Role of Magnetic Resonance Imaging in the Detection of Local Prostate Cancer Recurrence after External Beam Radiotherapy and Radical Prostatectomy

Wu, Lian Ming; Xu, Jianrong; Gu, Hanyang; Zhu, Jian; Chen, J.; Zhang, W.; Hu, Jiani

doi:10.1016/j.clon.2012.11.010

Cited by 67 publications

(49 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Local Recurrence to the Prostatic Fossa.-For the diagnosis of local recurrence to the prostatic fossa with MR imaging, the findings from a meta-analysis disclosed values for pooled sensitivity and specificity of 82% and 87% after radical prostatectomy and values of 82% and 74%, respectively, after external beam radiation (64). The diagnostic precision of 11 C-acetate in this setting strongly depends on the patient's PSA level and is higher after radical prostatectomy than after radiation therapy.…”

Section: Recurrence After Radical Treatmentmentioning

confidence: 99%

“…In humans, a radiolabeled gastrin-releasing peptide receptor antagonist (ie, 64 Cu-CB-TE2A-AR0) is rapidly cleared from the blood (initial half-life, 5 minutes) and excreted by the kidneys into the urinary bladder. Physiologic uptake can be observed mainly in the pancreas and, to a lesser extent, in the liver, spleen, and bowel.…”

Section: Gastrin-releasing Peptide Receptormentioning

confidence: 99%

“…Gastrin-releasing peptide receptor was shown to be overexpressed in many cancer types, including prostate cancer, while being scarce or nondetectable in normal prostate tissues. Its nonmammalian ligand, bombesin, was originally isolated from the skin of the European fire-bellied toad (Bombina bombina), and several radiolabeled analogs have been developed for PET and SPECT/CT imaging, including radiopharmaceuticals labeled with 18 F, 68 Ga,111 In, 99m Tc, 64 Cu, and lutetium 177 ( 177 Lu) (53). These tracers can be classified according to their pharmacodynamic effect on the gastrin-releasing peptide receptor.…”

Section: Gastrin-releasing Peptide Receptormentioning

confidence: 99%

See 2 more Smart Citations

Molecular Imaging of Prostate Cancer

Wibmer¹,

Burger²,

Sala³

et al. 2016

RadioGraphics

View full text Add to dashboard Cite

Prostate cancer is the most common noncutaneous malignancy among men in the Western world. The natural history and clinical course of prostate cancer are markedly diverse, ranging from small indolent intraprostatic lesions to highly aggressive disseminated disease. An understanding of this biologic heterogeneity is considered a necessary requisite in the quest for the adoption of precise and personalized management strategies. Molecular imaging offers the potential for noninvasive assessment of the biologic interactions underpinning prostate carcinogenesis. Currently, numerous molecular imaging probes are in clinical use or undergoing preclinical or clinical evaluation. These probes can be divided into those that image increased cell metabolism, those that target prostate cancer-specific membrane proteins and receptor molecules, and those that bind to the bone matrix adjacent to metastases to bone. The increased metabolism and vascular changes in prostate cancer cells can be evaluated with radiolabeled analogs of choline, acetate, glucose, amino acids, and nucleotides. The androgen receptor, prostate-specific membrane antigen, and gastrin-releasing peptide receptor (ie, bombesin) are overexpressed in prostate cancer and can be targeted by specific radiolabeled imaging probes. Because metastatic prostate cancer cells induce osteoblastic signaling pathways of adjacent bone tissue, bone-seeking radiotracers are sensitive tools for the detection of metastases to bone. Knowledge about the underlying biologic processes responsible for the phenotypes associated with the different stages of prostate cancer allows an appropriate choice of methods and helps avoid pitfalls. F-16b-fluoro5a-dihydrotestosterone, PSA = prostate-specific antigen, PSMA = prostate-specific membrane antigen

show abstract

Section: Recurrence After Radical Treatmentmentioning

confidence: 99%

Section: Gastrin-releasing Peptide Receptormentioning

confidence: 99%

Section: Gastrin-releasing Peptide Receptormentioning

confidence: 99%

See 1 more Smart Citation

Molecular Imaging of Prostate Cancer

Wibmer¹,

Burger²,

Sala³

et al. 2016

RadioGraphics

View full text Add to dashboard Cite

show abstract

“…МРТ предоставляет возможность детальной анатомической визуализации; в свою оче-редь, ПЭТ позволяет диагностировать опухолевые очаги. Как считают авторы исследований, комбинация данных методик способствует повышению точности проводимой диагностики [19,20].…”

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Алексеев¹,

Нюшко²,

Krasheninnikov³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

“…При разме-рах опухолей < 0,5 см 3 и > 2,0 см 3 и индексе Глисона < 6 чувствительность, специфичность и точность МРТ-диагностики составили 21-29, 43-54 и 67-75 %, при индексе Глисона 7 -63, 82-88 и 97 %, индексе Глисо-на > 8 -80, 93 и 100 % соответственно [15][16][17][18][19]. МРТ имеет некоторые ограничения в диагностике местных рецидивов после простатэктомии -трудности при ин-терпретации изменений, связанных с геморрагически-ми и воспалительными процессами, артефакты от ме-таллических скрепок [19][20][21][22][23][24][25] (рис. 1.…”

Section: Introductionunclassified